AMGEN Inc
NASDAQ: AMGN
$294.00
-$0.53 (-0.2%)
Closing Price on November 25, 2024
AMGN Articles
The November 30 short interest data have been compared with the previous report, and short interest was mixed in these selected stocks for this settlement date.
Published:
Last Updated:
24/7 Wall St. has reviewed the short interest data on the top biotech companies.
Published:
Last Updated:
The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.
Published:
Last Updated:
ThinkstockAmgen Inc. (NASDAQ: AMGN) released its third quarter earnings report Wednesday after the markets closed. The biotech giant had $2.72 in earnings per share (EPS) on $5.72 billion in revenue...
Published:
Last Updated:
Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.
Published:
The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
Published:
Amgen is slowly getting closer to an FDA final decision for its first-of-a-kind cancer therapy, talimogene laherparepvec (T-Vec).
Published:
Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech now.
Published:
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.
Published:
Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.
Published:
Independent research firm Argus has reviews of three of health care picks from its own Focus List in which it still sees significant upside ahead.
Published:
24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a single tweet did to them last week.
Published:
The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.
Published:
According to Fitch Ratings, biosimilars are beginning to take share from their reference biologics. This is seen in the debut of the first biosimilar drug in the United States.
Published:
Amgen and Xencor have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.
Published: